We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

After Foley Hoag’s prior updates regarding the chapter 11 bankruptcy cases of 23andMe Holding Co and its affiliated debtors ...

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, privacy concerns over 23andMe's genetic data, importance of biotechnology ...

A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led by the company's former CEO Anne Wojcicki, the company announced. The ...

23andMe co-founder and CEO Anne Wokcicki won back control of the genetic-test company after a prolonged bankruptcy fight that at one point was won by Regeneron.

"It has always been a sale of DNA to a third party." TTAM Research won a bankruptcy auction for 23andMe’s assets in June, overbidding a $265 million offer from Regeneron Pharmaceuticals (REGN.O).

In response to questions about the lawsuit, Regeneron, which is based in Tarrytown in New York's lower Hudson Valley, noted in a statement that the 23andMe bankruptcy auction has been reopened and ...

Genetic testing company 23andMe never hit on a sustainable business model and went bankrupt. Now, it's being sold to a non-profit launched by the co-founder, delaying addressing data privacy concerns.

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder and former chief executive, Anne Wojcicki.